| All Releases |
|---|
 |
XTENT, Inc. Receives Conditional Approval for Investigational Device Exemption of Custom NX(R) Drug Eluting Stent System from United States Food and Drug Administration
Jun 4, 2009
|
7.2 KB
|
| |
MENLO PARK, Calif., June 4, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. (Nasdaq: XTNT) today announced that the Company received conditional approval from the United States Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) authorizing it to begin its pivotal clinical program, composed of two piv...
|
|
|
XTENT, Inc. Announces Approval of Plan of Liquidation and Dissolution by Board of Directors and Filing of Proxy Materials With the SEC
May 15, 2009
|
8.3 KB
|
| |
MENLO PARK, Calif., May 15, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. ("XTENT" or the "Company") (Nasdaq: XTNT) today announced that its Board of Directors has determined, after consideration of potential strategic alternatives, that it is in the best interests of the Company and its stockholders to liquidate the Company's ...
|
|
|
XTENT Receives CE Mark Approval for CUSTOM NX (R) Drug-Eluting Stent System
Mar 19, 2009
|
8.1 KB
|
| |
MENLO PARK, Calif., March 19, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. (Nasdaq: XTNT) today announced that it has received CE Mark approval for its CUSTOM NX drug-eluting stent (DES) System. The CE Mark indicates that the CUSTOM NX DES System may be marketed in the European Union as well as other countries that recognize ...
|
|
|
XTENT Announces Fourth Quarter 2008 Financial Results and Business Progress
Feb 19, 2009
|
9.0 KB
|
| |
MENLO PARK, Calif., Feb 19, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc.
(Nasdaq: XTNT) today reported financial results for the fourth quarter and
year ended December 31, 2008 and provided an update on its business.
The company reported a net loss of $7.1 million, or $0.31 per share, for
the fourth quarter of 2008, compar...
|
|
|
XTENT to Retain Investment Bank to Pursue Strategic Alternatives
Jan 23, 2009
|
7.5 KB
|
| |
MENLO PARK, Calif., Jan 23, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. (Nasdaq: XTNT) today announced that it plans to engage an investment bank to help the company pursue strategic alternatives which may include the sale of some or all of the company's assets or other types of merger or acquisition transactions intended to ...
|
|
|
XTENT Announces Third Quarter 2008 Financial Results
Nov 4, 2008
|
9.4 KB
|
| |
MENLO PARK, Calif., Nov 04, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. (Nasdaq: XTNT) today reported financial results for the third quarter and nine months ended September 30, 2008.
The company reported a net loss of $8.7 million, or $0.37 per share, for the third quarter of 2008, compared to a net loss of $9.5 million,...
|
|
|
Custom NX(R) Drug Eluting Stent System Continues to Demonstrate Favorable Outcomes in Challenging Patient Populations at One, Two and Three Years
Oct 13, 2008
|
9.3 KB
|
| |
WASHINGTON and MENLO PARK, Calif., Oct 13, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. (Nasdaq: XTNT) today announced positive long-term follow-up data from the CUSTOM I, II and III clinical trials that reinforces the efficacy of the Custom NX(R) drug eluting stent (DES) system in treating patients with coronary artery diseas...
|
|
|
XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
Oct 10, 2008
|
7.3 KB
|
| |
WASHINGTON and MENLO PARK, Calif., Oct 10, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. (Nasdaq: XTNT) today announced that it plans to present long-term follow-up data from the CUSTOM I, II and III clinical trials next week at the Cardiovascular Research Foundation's (CRF) twentieth annual Transcatheter Cardiovascular Therape...
|
|
|
XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention
Aug 26, 2008
|
10.1 KB
|
| |
MENLO PARK, Calif., Aug 26, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. (Nasdaq: XTNT) today announced that the positive one-year follow-up data from the CUSTOM II trial was published in the most recent issue of the peer-reviewed journal, EuroIntervention. The lead author of the article was Dr. Pieter R. Stella, M.D., of Univ...
|
|
|
XTENT Announces Second Quarter 2008 Financial Results and Business Progress
Aug 6, 2008
|
11.5 KB
|
| |
MENLO PARK, Calif., Aug 06, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. (Nasdaq: XTNT) today reported financial results for the second quarter and six months ended June 30, 2008 and provided an update on its business.
The company reported a net loss of $12.9 million, or $0.56 per share, for the second quarter of 2008, com...
|
|
|
XTENT Appoints Christopher M. Smith and Arthur T. Taylor to Board of Directors
Jun 20, 2008
|
7.7 KB
|
| |
MENLO PARK, Calif., June 20, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. (Nasdaq: XTNT) announced today that Christopher M. Smith and Arthur T. Taylor have been appointed to the company's board of directors.
"We expect to benefit greatly from the complementary skill sets that Chris and Art will add to our board of directo...
|
|
|
XTENT Announces CUSTOM I Data Receives Recognition from EuroIntervention
Jun 17, 2008
|
9.1 KB
|
| |
MENLO PARK, Calif., June 17, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. (Nasdaq: XTNT) today announced that the CUSTOM I two-year data that was published in the current issue of EuroIntervention was recognized by the journal's editorial board as one of the six best papers submitted to the journal this past winter. Lutz Buell...
|
|
|
XTENT Announces European Regulatory Update
Jun 12, 2008
|
7.4 KB
|
| |
MENLO PARK, Calif., June 12, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. (Nasdaq: XTNT) today announced a progress update regarding its application to the designated European Notified Body for CE Mark approval of its Custom NX(R) DES System. XTENT's European Notified Body confirmed that recently presented six-month follow up ...
|
|
|
XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
May 13, 2008
|
10.3 KB
|
| |
BARCELONA, Spain and MENLO PARK, Calif., May 13, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. (Nasdaq: XTNT) today announced positive six-month follow-up data from the CUSTOM III clinical trial, which assessed the safety and efficacy of the Custom NX(R) drug eluting stent (DES) system for the treatment of patients with coronar...
|
|
|
XTENT Announces Clinical Trial Data to be Presented at Annual EuroPCR Meeting Next Week
May 7, 2008
|
10.5 KB
|
| |
MENLO PARK, Calif., May 7, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. (Nasdaq: XTNT) today announced that six-month follow-up data from the CUSTOM III trial will be presented at EuroPCR, taking place May 13 to 16 in Barcelona. The company will hold a webcast and conference call to review the new CUSTOM III data immediately f...
|
|
|
XTENT Announces First Quarter 2008 Financial Results
Apr 28, 2008
|
11.0 KB
|
| |
MENLO PARK, Calif., April 28, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. (Nasdaq: XTNT) today reported financial results for the first quarter ended March 31, 2008.
The company reported a net loss of $12.5 million, or $0.54 per share, for the first quarter of 2008, compared to a net loss of $7.9 million, or $0.55 per sha...
|
|
|
XTENT to Present at Cowen and Company's 28th Annual Health Care Conference
Mar 12, 2008
|
5.5 KB
|
| |
MENLO PARK, Calif., March 12, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. (Nasdaq: XTNT) today announced that Gregory D. Casciaro, President and Chief Executive Officer, will present at Cowen and Company's 28th Annual Health Care Conference on Tuesday, March 18, 2008 at 9:30 a.m. Eastern. This event will be held at the Boston...
|
|
|
XTENT Announces 2007 Financial Results
Feb 19, 2008
|
12.5 KB
|
| |
MENLO PARK, Calif., Feb 19, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. (Nasdaq: XTNT) today reported financial results for the fourth quarter and year ended December 31, 2007.
The company reported a net loss and net loss attributable to common stockholders of $11.9 million, or $0.52 per share, for the fourth quarter of 2...
|
|
|
XTENT Announces 2007 Financial Results Conference Call
Feb 12, 2008
|
6.2 KB
|
| |
MENLO PARK, Calif., Feb 12, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. (Nasdaq: XTNT) announced that it will report its financial results for 2007 after market close on Tuesday, February 19, 2008. The company will hold a conference call the same day at 2 p.m., Pacific Time (5 p.m. Eastern Time). The call will be hosted by Gr...
|
|
|
XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe
Dec 27, 2007
|
8.4 KB
|
| |
MENLO PARK, Calif., Dec 27, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. (Nasdaq: XTNT), the developer of customizable drug-eluting stent (DES) systems, today announced that it has submitted its application to the designated European Notified Body for CE Mark approval of its Custom NX DES System.
XTENT's CE Mark applicatio...
|
|
|
